Latest Medical Devices News

Anteris Technologies has secured regulatory green lights for its pivotal PARADIGM trial and raised $25.2 million in capital, advancing its innovative DurAVR® transcatheter heart valve towards commercialisation.

BTC Health has reissued its Chairman’s Address with added financial details, highlighting a strategic shift towards diversified medical products and a strong start to FY26 with 36% revenue growth.

Control Bionics Limited is set to acquire the remaining stake in Neuro Elite Athletics, integrating the NeuroBounce athletic performance program with its EMG technology to accelerate growth in key markets.

Vitasora Health has secured AU$3.56 million from a cornerstone investor, issuing over 118 million shares, while confirming compliance with key regulatory disclosure obligations.

Control Bionics has secured $3.25 million through a discounted share placement, aiming to boost its assistive and neurotechnology product growth globally.

BTC Health has broadened its medical product portfolio through strategic acquisitions and organic growth, reporting strong early revenue gains while cautiously navigating the uncertain timing of ECMO system adoption.

Singular Health has submitted a 510(k) premarket notification to the FDA for its enhanced 3DICOM MD Cloud platform, aiming to expand imaging capabilities and introduce a scalable, cloud-native solution for medical image management.

BTC Health has raised $2 million through a share placement priced at a slight premium, with director Martin Kahanovitz participating and a new South African investor joining the register.

Uscom Limited reported a 25% revenue decline in FY25 amid global geopolitical challenges but reinforced its commitment to growth through strategic partnerships and innovative medical technologies.

SDI Limited reported a steady FY2025 with a slight profit increase, driven by growth in aesthetic and whitening products and the launch of its new amalgam replacement, Stela. The company also announced plans for a new factory to boost production capacity.

ReNerve Ltd reports a strong 53% year-on-year revenue increase, expanding its US distribution network and advancing clinical studies for its nerve repair products. The company is poised for significant global market growth with new partnerships and upcoming product launches.

Anteris Technologies Global Corp. has filed a Form S-1 registration statement with the SEC to enable resale of shares issued in a recent private placement, marking a key step in advancing its DurAVR transcatheter heart valve system and pivotal clinical trials.